Alvotech
ALVOW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001898416
No open-market purchases or sales by Alvotech insiders were filed in the last 90 days; 7 institutions reported holding it in 13F filings for Q2 2026, worth $1.16M in total; Oaktree Capital is the only superinvestor holding it.
Other share classesALVO
Q4 2022 vs. Q3 2022
How the institutions holding Alvotech changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 26 | 1 | 23 | −2 |
| Shares | 6.39M | 400.0K | 6.17M | +178.7K (+3.0%) |
| Value | $4.54M | $279.0K | $5.39M | +$1.12M (+26.4%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (2)
Institutions that held Alvotech at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| CSS LLC | 61,875 | $57.5K | 0.00% |
| Clear Street LLC | 4,695 | $4.00K | 0.00% |
Sold out (4)
Institutions that held Alvotech at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Sona Asset Management (US) LLC | 53,027 | $37.0K |
| Verition Fund Management LLC | 42,500 | $28.0K |
| Susquehanna International Group, LLP | 41,233 | $27.0K |
| Radcliffe Capital Management, L.P. | 73,073 | – |
Not filed for Q4 2022 yet (1)
Institutions that held Alvotech at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Serengeti Asset Management LP | 400,000 | $279.0K |